Connect with us

Breaking

FDA‘s review of epilepsy drug could bring windfall to CBD companies

Published

on

(FinancialPress) — This summer is set to leave a landmark for the cannabis industry. The Food and Drug administration prepares to give its ruling on the first drug derivated from the plant.

Epidiolex, an epilepsy therapeutic drug made cannabis-extracted cannabidiol, could vanquish decades of propaganda by the government about the plant‘s alleged lack of medical benefits.

The UK‘s GW Pharmaceuticals is the company behind the request for approval to the FDA, looking to commercialize its product in the United States.

The date set for the public hearing and review of evidence regarding the issue is set for this Thursday. While the final decision will only be made come summer, the FDA will gather a group of independent experts this week to review the product. This signals that, while the Agency is open to evaluate the request, it will do so with extreme caution – understandable, it being a cannabis drug aimed at children.

Several cannabis businesses were inquired about their views on this hot topic for the industry. What they see as the top five points of contention can be condensed as follows:

  1. How the drug is manufactured: GW Pharma has gone on record stating that it will not try to interfere with businesses or individuals that look to manufacture “artisanal CBD“. However, the industry at large will be looking closely at how the hearing goes as far as attempts of obtaining blanket exclusivity on the product‘s formulation. “The hemp industry should be focused on ways it can co-exist with a pharmaceutical product,” said Garett Graff, a hemp attorney for Denver-based Hoban Law Group.
  2. Availability: How quickly can the company meet a sudden rise in demand
  3. Rescheduling of cannabis by the DEA: while the FDA will not define the rescheduling of cannabis if they grant approval for the drug, the industry believes that the two things go hand in hand.
  4. Edibles: the industry will look for hints that may point to the FDA looking to apply pharmaceutical oversight to CBD in food products.
  5. Patents: GW Pharma has requested a battery of patents. While the FDA does not define if they are granted, the topic will be brought up and the industry will be looking at conversation revolving that particular topic.

Ruben is a South American writer who focuses on the state of the cryptocurrency, cannabis and tech industries worldwide.

Breaking

Quanta’s Polarized CBD: Where Plants Meet Quantum Physics

Published

on

CBD, the short name for cannabidiol, remains a hot topic today in the consumer and investment spaces.  Companies are packing the component of hemp and cannabis touted for its powerful positive benefits into a litany of products, ranging from creams to gummies to medicines to food and beverages and everywhere in between.  Why?  Because consumer demand is soaring and the recent passage of the Farm Bill made hemp-derived CBD completely legal, opening up interstate commerce without fears of prosecution.

CBD, which doesn’t contain any of the psychoactive components that result in the “high” frequently associated with cannabis, has a therapeutic index that goes from alleviating symptoms of hard-to-treat diseases like epilepsy to anti-aging skin properties.

This segment of the so-called “green rush” – used to describe cannabis reform sweeping the planet – could be growing faster than the legal marijuana market.  Owing to increased consumer awareness about CBD’s uses and safety profile and relaxed hemp regulations, industry analysts at the Brightfield Group forecast that the hemp-derived CBD market could swell to $22 billion by 2022 from about $580 million in 2018.

At Quanta, Inc. (OTC: QNTA), scientists are using quantum physics to manipulate and stabilize electron spin in naturally occurring elements, including CBD, to increase performance in the body.  The result is CBD that is “polarized,” which brings with it a bevy of benefits that essentially amplify the properties of CBD in a consistent and repeatable fashion.  This means products using polarized CBD are faster acting with stronger healing power that last longer without making a person tired compared to competitor’s products.

Many companies tout increased “bioavailability,” meaning that the active ingredient in their product reaches its target in a more efficient way.  Others have trumpeted innovation in increasing bioenergy (or bio-activity), increasing the physical energy and effectiveness of any percentage of CBD available. 

Burbank, California-based Quanta takes it a step further, saying that its technology is the first to “increase and sustain” bio-activity in CBD.  The applied science company’s flagship product is a muscle rub, a combination of 13 natural ingredients, including, but not limited to, CBD, arnica, turmeric, ginger and sunflower oil.  Aptly branded as “Quanta CBD Muscle Rub,” the proprietary blend of the ingredients maximizes anti-inflammatory relief and circulation while easing aches and pains in muscles and joints for comfort and overall well-being.

Quanta also sells an ultra-premium CBD vape cartridge containing hemp-derived CBD.

According to Quanta, sales of the premium organic rub are improving dramatically since the initial launch just over five months ago.  The company sells the balm through its ecommerce channels in addition to being available in more than 300 doctor’s offices, 100 pharmacies and over 150 retail shops.

Quanta CEO Eric Rice didn’t provide specifics, but did say earlier this month that the muscle rub has built a loyal customer base that has helped bolster sales 70% month-over-month since launch.

Rice added that they are working on adding more distribution partners, including ongoing discussions with several national fitness centers, hospital networks and pain management centers.  The company is also planning to add more products to the portfolio using its polarization technology, for which it will manufacture its own line of CBD products in-house.  The company made the shift in business model from licensing CBD brands to the more lucrative model of manufacturing its own products subsequent to the passing of the Farm Bill.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

Driven Deliveries Lands Former Amazon and Facebook Exec as COO

Published

on

If Driven Deliveries (OTC: DRVD) moves as quickly making legal cannabis deliveries as it does building its business, customers should be very well served.  In less than five months, the company has made strides to execute on its business model, including entering into and completing a merger that made Driven the first and only publicly traded cannabis delivery company.

Driven Deliveries (née Results Based Outsourcing, “RBOS”) in January completed the name and ticker change to reflect the new public company, following that with a 12.35-for-1 forward stock split this month to increase visibility in liquidity in the stock.

Driven Deliveries provides a turnkey solution to its dispensary partners.  Through the application, customers simply find the products they want, order it online and wait for the delivery to arrive from Driven.

Currently, the San Diego-based “GrubHub for cannabis,” is focusing its growth efforts in the massive market of its home state where medical cannabis has been allowed for two decades and recreational marijuana was legalized in January 2018.  California has an economy that would rank it sixth in the world if it were a country and its cannabis market is reflective of this mass.  To that point, the industry experts at BDS Analytics forecast California’s legal cannabis market to reach $5.0 billion in 2019.

Earlier this month, Driven Deliveries significantly expanded its footprint in the Golden State by establishing relationships with four cannabis retailers in some of California’s largest markets.  Through existing and new relationships with licensed retailers, Driven will now have the ability to serve customers in the Bay Area, Central California, Sacramento, and in the Orange County and Los Angeles areas, with the potential for additional expansion.

Furthermore, DRVD management, led by successful industry entrepreneur Chris Boudreau, is planning to establish operations in neighboring states, Nevada and Arizona, as well as Michigan, which in November legalized recreational marijuana.

Boudreau, who helped build California’s Kindest into one the largest retail delivery cannabis companies and Sunstone Distribution into California’s first statewide wholesale cannabis distribution company, attracted some top talent this month with his business plan.  On Tuesday, Driven Deliveries announced that Jerrin James has joined the company as Chief Operating Officer.

James is a highly accomplished global logistics and supply chain executive, leading operations for industry juggernauts like Amazon, Groupon and Facebook.  Before joining Driven Deliveries, James was Head of Logistics at Facebook with global responsibility.

Calling Driven an amazing opportunity, James explained, “We have a jump start on the fastest growing industry in the world as the first publicly traded delivery business in cannabis.”  Given his expertise in supply chains and logistics for high-growth companies, it’s fair to say that James’ opinion and decision to join Driven Deliveries carries some extra weight.  Investors will surely be looking to see what’s next for this upstart building a team aggressively taking aim at capturing share in a steadily emerging – and very large – market.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

MassRoots Expands Product Portfolio with New Partner and Acquisition of COWA Science

Published

on

With predictions that the legal cannabis market will experience non-linear growth in the coming years underscored by ongoing legalization of marijuana worldwide, companies big and small are hustling to build their footprints to capture share in a market that  Grand View Research forecasts will reach $146.4 billion by the end of 2025 (from $7.1 billion in 2016).  Whether companies are touching the once-taboo plant or operating in an ancillary segment, there is no shortfall of growth opportunities as part of an abolishment of eight decades of cannabis prohibition.

For its part, MassRoots (OTCQB: MSRT), a technology and rewards platform at its core, is branching out into different verticals.  Since the start of 2019, the company has penned two substantive agreements that have expanded MassRoots’ portfolio of products and services.

In mid-January, the Los Angeles-based company partnered with We are Kured, a subsidiary of New Age Brands (CSE: NF)(OTC:NWGFF), to serve as the leading online retailer of We are Kured’s best-selling CBD Pen.   The handheld vaporizer pen dispenses cannabidiol, or CBD, a THC-free constituent of hemp and cannabis trumpeted for its therapeutic benefits relating to alleviating inflammation, pain, anxiety, seizures and a host of other symptoms from a variety of maladies without unpleasant side effects or psychotropic buzz often associated with marijuana. 

The pen represents a new revenue stream for MassRoots as the first CBD product to be sold directly through the company’s online platform and social media pages.  MassRoots has more than one million social media followers, in excess of 750,000 email subscribers and hundreds of thousands of unique monthly visitors on its website and application to whom it can market the product.

This month, MassRoots entered a definitive agreement to acquire supply-chain as a service company COWA Science Corp. in an all-stock deal valued at approximately $5.78 million.  The buyout terms are dependent upon COWA Science meeting annual revenue milestones of $2.5 million and $7.5 million, as well as other customary closing conditions.  In short, the terms specify that COWA shareholders are entitled to additional shares if the sales milestones are hit within three years of the effectiveness of the merger.

For 2018, unaudited financials show COWA Science generated revenue of approximately $1.5 million by providing a variety of products and services to its list of about 50 cannabis- and hemp-focused clients.  Upon completion of the transaction, COWA will become a wholly-owned subsidiary of MassRoots.

MassRoots expects the acquisition to be immediately accretive while diversifying its business.  Management expects to build upon the existing COWA Science business to offer a complete cannabis-centric suite covering the full supply chain, including advertising, consumer packaging, process and product development, growing supplements and nutrients, HVAC and more.  On the whole, the new, bigger MassRoots intends to provide a broad mix of offerings to hundreds of licensed cannabis business in key markets across the country.

“Going forward, MassRoots is confident that the addition of COWA Science will increase overall revenues and expand our market presence, with the goal of generating positive cash-flows from operations,” commented MassRoots CEO Isaac Dietrich in the press release on the acquisition.  Dietrich added that the decision to bring COWA Science under his company’s umbrella came after several years of following their business and growth trajectory.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Most Popular